Should I buy Sun Pharma Advanced Research Company Ltd stock at the current price?

Whether to buy Sun Pharma Advanced Research Company Ltd stock at ₹123.96 depends on multiple factors including P/E ratio of 0.00, P/B ratio of N/A, and your investment goals. Consult a financial advisor for personalized advice.

What are the key financial ratios of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd's key metrics include P/E Ratio: 0.00, P/B Ratio: N/A, ROE: -84.04%, ROCE: -279.00%, EPS: ₹-8.23, and Debt-to-Equity: 0.49.

How is Sun Pharma Advanced Research Company Ltd stock performing today?

Sun Pharma Advanced Research Company Ltd opened at ₹124.08 and is trading at ₹123.96, showing a decline of 0.10% with volume of 2,66,190 shares.

What is the P/E ratio of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd has a P/E ratio of 0.00, meaning investors pay ₹0.00 for every ₹1 of earnings. With EPS of ₹-8.23, compare this with industry peers for better context.

What is the market capitalization of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd has a market cap of ₹4,356.7 crores, making it a small-cap company.

What is the book value and P/B ratio of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd has a book value of ₹3.88 per share and P/B ratio of N/A. Current price is ₹123.96.

Search For Features

Stocks

Intraday Booster

Sector Booster

Stock Screener

Market Pulse

Screeners

Go Prime

My Plans

Contact

Refer & Earn

Screeners

Main

Stock Screener

Create Screener

Explore Screeners

Community Screeners

Trading Screeners

CandleSticks Screener

Top Gainers & Losers

Opening Range Breakout

Stock Screener AI

Stock Quality Scorecard

Overvalued StocksNew

Undervalued StocksNew

Technical Screeners

NR4 Stocks

NR7 Stocks

Previous Day High Breakout

Previous Day Low Breakout

Previous Day Open Breakout

Bullish Crossover Stocks

Bearish Crossover Stocks

High Volume Shocker

VWAP Breakout Stocks

Range High Breakout

Range Low Breakout

Markets

Global Market Today

Global Indices

Indian Indices

NIfty Today

Smart Money

FII DII DataNew

FII Buying

NSE Insider Trading

SLB Stocks Data

Derivatives

FnO Movements

NSE F&O Lot Size

Ban List

Analysis & Calendars

Technical Dashboard

Sector Booster

Sector AnalysisNew

Result Calendar

Economic Calendar

Sun Pharma Advanced Research Company

Small Cap•409 Employees•IPO 2007

Chart

Current Price

₹123.96

-0.12 (-0.1%)Updated

NSE :SPARC

BSE :532872

Sector :Pharmaceuticals

Today's Range

₹123.11

₹123.96

₹127.28

52 Week Range

52W Low₹116.45

52W High₹204.40

₹123.96

Downside6.45%

Upside64.89%

Chart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap

₹4,356.7 Cr

Market Cap

Total market value of company

P/E Ratio

Price to Earnings. Lower is generally better (<25 is good)

P/B Ratio

97.87

P/B Ratio

Price to Book Value. <3 may indicate undervaluation

EPS

₹-8.23

EPS

Earnings Per Share. Higher and growing is positive

Profitability

ROE

-84.04%

ROE

Return on Equity. >15% is good, >20% is excellent

ROCE

-279.00%

ROCE

Return on Capital Employed. >15% is good

Net Margin

-447.99%

Net Margin

Net profit as % of revenue. >10% is good

Operating Margin

Operating profit margin. >15% is good

Growth

EPS Growth (5Y)

5-year EPS growth. >15% is strong

Revenue Growth (5Y)

-1.35%

Revenue Growth (5Y)

5-year revenue growth. >10% is good

Qtr Sales Growth

-42.60%

Qtr Sales Growth

Quarter-over-quarter sales growth

Qtr Profit Growth

45.90%

Qtr Profit Growth

Quarter-over-quarter profit growth

Financial Health

Debt/Equity

0.49

Debt/Equity

Financial leverage. <1 is good, <0.5 is excellent

Book Value

₹3.88

Book Value

Net asset value per share

Dividend Yield

Annual dividend as % of price. >2% is good

Promoter Holding

65.70%

Promoter Holding

Promoter stake. >50% shows confidence

Good

Average

Needs Attention

SWOT Analysis

Strengths

4 points

•High promoter holding at 65.7% indicates strong leadership confidence.
•Operates in the resilient Pharmaceuticals sector with consistent demand.

Weaknesses

5 points

•Deeply negative ROE (-84.04%) and ROCE (-279.00%) indicate severe unprofitability.
•Significant decline in quarterly sales (-42.60%) and 3-year revenue growth (-19.44%).

Opportunities

4 points

•Growing global healthcare spending and demand for innovative treatments.
•Opportunity to commercialize diverse pipeline of novel drugs and therapies.

Threats

4 points

•Intense competition from established pharmaceutical players in global markets.
•High R&D costs, lengthy trials, and risk of regulatory approval failure.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

Level	Price	Distance	% Change
R4	₹134.80	+₹10.84	+8.74%
R3	₹130.63	+₹6.67	+5.38%
R2	₹128.95	+₹4.99	+4.03%
R1	₹126.46	+₹2.50	+2.01%
PIVOT	₹124.78	0.82	0.66%
CURRENT	₹123.96	-	-
S1	₹113.95	-₹10.01	-8.08%
S2	₹118.12	-₹5.84	-4.71%
S3	₹120.61	-₹3.35	-2.70%
S4	₹122.29	-₹1.67	-1.35%

CPR Levels

Support

Resistance

| CPR |

BC: N/AP: N/ATC: N/A

LTP: N/A

PDH: N/A

PDL: N/A

● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume

2.66L

(06 Mar 2026)

-36.1% vs avg

Delivery %

46.7%

(06 Mar 2026)

+3.1% vs avg

Avg Volume (20D)

4.17L

(06 Feb - 06 Mar)

20-day average

Avg Delivery %

43.6%

(06 Feb - 06 Mar)

Trend ↑

Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap

Sun Pharmaceutical Industries Ltd

4.12L ₹ Cr

Best Profit Growth

Shilpa Medicare Ltd

234.00 %

Highest Dividend Yield

RPG Life Sciences Ltd

1.22 %

Peer Comparison

Company Name
Aarti Drugs Ltd
Aarti Pharmalabs Ltd
Blue Jet Healthcare Ltd
FDC Ltd
Gufic BioSciences Ltd
Orchid Pharma Ltd
RPG Life Sciences Ltd
Senores Pharmaceuticals Ltd
Sequent Scientific Ltd
Shilpa Medicare Ltd
SMS Pharmaceuticals Ltd
Solara Active Pharma Sciences Ltd
Sun Pharmaceutical Industries Ltd
Supriya Lifescience Ltd
Unichem Laboratories Ltd
Zota Health Care Ltd

About

Sun Pharma Advanced Research Company Ltd

SPARC (Sun Pharma Advanced Research Company Limited) is a clinical-stage biopharmaceutical company headquartered in Mumbai, India, focusing on the research and development of novel pharmaceutical products for global markets. Their core therapeutic areas of concentration are oncology, neurodegeneration, and immunology, reflecting a commitment to addressing significant unmet medical needs across diverse disease areas.

A significant portion of SPARC's business involves advancing a robust pipeline of drug candidates through various clinical trial phases. This includes Elepsia XR for epilepsy, PDP-716 for open-angle glaucoma, and Sezaby for neonatal seizures. These products represent different stages of development, highlighting SPARC's commitment to a diversified approach to drug discovery and development.

In the oncology space, SPARC is actively pursuing the development of Vodobatinib, a c-ABL inhibitor. This compound is in phase 2 clinical trials for Parkinson's disease, has completed phase 1 trials for Lewy body dementia, and is currently in preclinical development for Alzheimer's disease. Further, they are developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, targeting refractory chronic myelogenous leukemia, also in phase 2 clinical trials.

SPARC's commitment to immunology is showcased by the development of Vibozilimod (SCD-044), a selective S1PR1 agonist currently in phase 2 trials for psoriasis and atopic dermatitis. The company also has preclinical stage candidates in development, including SCD-153 for alopecia areata and SBO-154, an anti-MUC-1 antibody-drug conjugate (ADC) targeting multiple tumor types. This demonstrates a long-term strategic vision for growth within this therapeutic area.

In summary, SPARC's business model centers on the innovative research, development, and clinical advancement of a diverse portfolio of pharmaceutical products across several key therapeutic areas. Their pipeline, ranging from preclinical to phase 2 trials, positions them for potential future growth and market expansion in the global biopharmaceutical industry. The company's focus on unmet medical needs underscores its commitment to improving patient outcomes.

COMPANY FACTS - SPARC

Registered Address

17B Mahal Industrial Estate, Mahakali Caves Road, Andheri (East)

Mumbai

MAHARASHTRA

Tel: 912266455645

Website:https://www.sparc.life/

Investor Relations:http://www.sparc.life/financials

Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 409

IPO Date: 18/07/2007

MANAGEMENT - SPARC

Mr. Dilip Shanghvi

Non-Executive Chairman of the Board

Mr. Anilkumar Raghavan

Chief Executive Officer

Mr. Anup Rathi

Chief Financial Officer

Dr. Nitin Dharmadhikari

Chief Operating Officer

Ms. Kajal Damania

Compliance Officer, Company Secretary

Dr. Thennati Rajamannar

Non-Executive Director

Ms. Vidhi Shanghvi

Additional Non-Executive Non-Independent Director

Mr. Sudhir Valia

Non-Executive Director

Smt. Bhavna Doshi

Non-Executive Independent Director

Dr. Ferzaan Engineer

Non-Executive Independent Director

Dr. Robert Spiegel

Non-Executive Independent Director

Mr. Jaydeep Issrani

Investor Relations

Investor Questions Answered

Sun Pharma Advanced Research Company Ltd (SPARC) Stock FAQs

Get answers to the most common questions about Sun Pharma Advanced Research Company Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Sun Pharma Advanced Research Company Ltd (SPARC) is ₹123.96. Today, the stock has declined by ₹0.12 (0.10%), trading in a range of ₹123.11 to ₹127.28. The stock opened at ₹124.08 with a trading volume of 2,66,190 shares.

Sun Pharma Advanced Research Company Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,356.7 crores, P/E ratio of 0.00, ROE of -84.04%, and ROCE of -279.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

The 52-week high price of Sun Pharma Advanced Research Company Ltd (SPARC) is ₹204.4, while the 52-week low is ₹116.45. Currently trading at ₹123.96, the stock is 8.5% away from its 52-week low and 39.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

Whether to buy Sun Pharma Advanced Research Company Ltd stock at ₹123.96 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a loss of 0.10%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

Sun Pharma Advanced Research Company Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹123.96, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

Sun Pharma Advanced Research Company Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: -84.04%, ROCE: -279.00%, Dividend Yield: 0.00%, EPS: ₹-8.23, Book Value: ₹3.88, Debt-to-Equity: 0.49, and Current Ratio: N/A. The company's market cap stands at ₹4,356.7 crores. These metrics help evaluate the company's valuation, profitability, and financial health.

Sun Pharma Advanced Research Company Ltd stock opened at ₹124.08 and is currently trading at ₹123.96, showing a decline of ₹0.12 (0.10%). The intraday high is ₹127.28 and low is ₹123.11. The trading volume stands at 2,66,190 shares, indicating moderate market participation today.

Sun Pharma Advanced Research Company Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-8.23, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.

Sun Pharma Advanced Research Company Ltd has a market capitalization of ₹4,356.7 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹123.96) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.

Sun Pharma Advanced Research Company Ltd has a book value of ₹3.88 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹123.96, which is 3094.8% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.

Sun Pharma Advanced Research Company Ltd has a Return on Equity (ROE) of -84.04% and Return on Capital Employed (ROCE) of -279.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.

Sun Pharma Advanced Research Company Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.

Sun Pharma Advanced Research Company Ltd has a debt-to-equity ratio of 0.49, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.

Sun Pharma Advanced Research Company Ltd has an Earnings Per Share (EPS) of ₹-8.23, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹123.96 and P/E ratio of 0.00, investors are paying 0.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.

Sun Pharma Advanced Research Company Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.

Sun Pharma Advanced Research Company Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.

To analyze Sun Pharma Advanced Research Company Ltd stock, consider: 1) Fundamental Analysis - Review P/E (0.00), ROE (-84.04%), debt-to-equity (0.49), and growth rates. 2) Technical Analysis - Check 52-week range (₹116.45 - ₹204.40), moving averages, and chart patterns. 3) Valuation - Compare current price (₹123.96) with book value (₹3.88) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.

The face value (or par value) of Sun Pharma Advanced Research Company Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹123.96 is 12296x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.

Investing in Sun Pharma Advanced Research Company Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹116.45 - ₹204.40). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.49 indicates leverage. 4) Liquidity Risk - Based on trading volume of 2,66,190 shares. 5) Valuation Risk - P/E of 0.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.

Sun Pharma Advanced Research Company Ltd operates in the industry with key metrics: P/E ratio of 0.00, ROE of -84.04%, market cap of ₹4,356.7 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.49), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.

Target prices for Sun Pharma Advanced Research Company Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹123.96, with a 52-week range of ₹116.45 to ₹204.40. Based on fundamentals like P/E (0.00), ROE (-84.04%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.

Consider selling Sun Pharma Advanced Research Company Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹123.96. 2) Fundamental Deterioration - Declining ROE (currently -84.04%), increasing debt (D/E: 0.49), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.

Tax implications for Sun Pharma Advanced Research Company Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.